CS Paper Radar

Predicting Dose-Response Success from Primary Screening Data

Sean Lim

cs.LG q-bio.BM ·submitted 2026-08-27 02:18 UTC · v2

Abstract

High-throughput drug screening uses inexpensive primary screens to select compounds for more costly follow-up dose-response experiments, which estimate compound potency (pXC50) by determining the concentration required to produce a specified biological effect. However, many promoted compounds fail to yield a reportable potency, even when activity is subsequently confirmed. We investigated whether inexpensive three-point primary-screening data could predict whether a more costly 11-point dose-response experiment would yield a reportable pXC50. Using a dataset of 32,971 compound-assay pairs with three-point primary-screening and 11-point dose-response measurements, we trained random-forest models to predict successful potency quantification. Our model achieved an AUROC of 0.939 +/- 0.002 and generalized to previously unseen chemical scaffolds and assay-mechanism families. We found that primary-screen response features were more predictive of dose-response quantifiability than molecular structure-based features. Successful potency quantification was also strongly associated with primary-screen response amplitude. Across eight chronological test releases, the model retrospectively retained 90% of reportable potencies while selecting only 55.7% of historically promoted compound-assay pairs for follow-up profiling. These findings suggest that predicting potency quantifiability from primary-screening data could improve the efficiency of compound prioritization and reduce unnecessary dose-response experiments.

Comment
Format changed. Some information added

Closest papers

Nearest neighbours by meaning across the whole index.

D2ML: Models for Direct-to-Biology Small Molecule Screening

cs.LG q-bio.BM ·2026-10-29 ·AkshatKumar Nigam, Neri Amara, Hillary Dequina, Dyana Kenanova, Seth Malmersjo +5 more
published similarity 0.74
Abstract · NeurIPS 2026 Workshop on AI for Drug Discovery (AI4DD)

Direct-to-biology (D2B) screening enables rapid testing of newly synthesized molecules without purification. However, uncertain concentrations in crude mixtures and limited purified-compound measurements complicate the use of these data in machine learning. Here we show that models tailored to the structure of D2B data can improve prediction and guide the discovery of more potent and selective compounds. Our assay-aware models predict activity from single-point screens, relative potency across targets from crude dose-response assays, and absolute potency from purified-compound measurements. For crude assays, potency ratios between targets tested from the same well can retain selectivity information despite uncertain concentrations. A joint model that shares information across stages and balances their contributions to training improved predictions over separate neural networks. The largest gain was in crude dose-response selectivity prediction, where rank correlation increased from 0.27 to 0.40. In a separate experiment, independently trained models guided the selection of 84 new compounds to improve ROS1 potency while limiting activity against the anti-target TRKB. Synthesis and testing identified compounds that extended the measured Pareto front, achieving better combinations of potency and selectivity than those in the training data. The most selective new compound achieved a ROS1 IC50 of 14.7 nM and 233-fold selectivity over TRKB. By comparison, the most selective training compound had a ROS1 IC50 of 20.3 nM and 79-fold selectivity. ATLAS provides the experimental setting for this approach, supporting synthesis and screening of 1,000-10,000 model-selected compounds in two- to three-week cycles. Together, these results show how assay-aware learning can use the full D2B assay sequence to guide multi-objective molecular optimization.

0.16

The Dose Makes the Poison: Exposure-Aware Evaluation of Generative Drug Design

cs.AI q-bio.QMcs.LG ·2026-11-10 ·Maria Franz, N. Benjamin Erichson
published similarity 0.65
Abstract · 14 pages, 3 figures. Accepted at the AI4DD workshop (AI for Drug Discovery: Bridging the Translation Gap), NeurIPS 2026

Generative models are increasingly used to propose molecules for drug discovery. They can produce far more candidates than can be experimentally tested, making computational selection essential. Most selection methods rely on predicted molecular properties, such as potency and toxicity, but overlook how these properties translate into drug exposure at a given dose. As a result, molecules that appear promising on paper may require impractical doses or raise safety concerns. We investigate this gap by using physiologically based pharmacokinetic (PBPK) simulations to re-evaluate molecules selected from three PARP1-targeted generative pipelines. Of 60 shortlisted molecules, seven fail to achieve sufficient target exposure, while 28% of the remaining candidates show predicted safety risks at their required dose. Moreover, 85% of candidates with an achievable dose are outperformed by molecules overlooked during static selection. These findings suggest that accounting for dose and exposure can substantially change which generated molecules are considered promising for drug development.

0.32

ScreenShot: A Foundation Model for Few-Shot Combination Drug Screening

cs.LG ·2026-08-12 ·Antoine de Mathelin, Christopher Tosh, Wesley Tansey
code/data similarity 0.64
Abstract

Treating patients with combinations of drugs reduces the risk of resistance to any individual drug. Finding effective combinations is difficult because the large search space makes combinatorial screens prohibitively expensive, time consuming, and often technically infeasible. Predictive models can fill this gap, yet existing methods typically require molecular profiling of each sample and per-cohort training, limiting their applicability when time and tissue are scarce. To address this challenge, we introduce ScreenShot, a hierarchical transformer pretrained on 40 drug screening datasets covering 3,700 drugs and 6,000 biological samples, whose architecture mirrors the nested structure of screening data. Given a few-shot context of observations from a new patient, ScreenShot predicts the response of the sample to combination therapies through in-context learning, operating directly on functional measurements with no fine-tuning and no molecular profiling. On four held-out datasets, ScreenShot outperforms all baselines in both prediction accuracy and identification of selectively effective treatments. ScreenShot's internal representations are directly useful for experimental design: we use them to drive a weighted k-means++ active learning strategy that selects which experiments to run, achieving the same hit detection as uniform screening with a third of the budget. Source code and interactive dashboard: https://github.com/tansey-lab/screenshot.

0.24

Calibrated Uncertainty Quantification on TDC ADMET: What Can Be Resolved Across 22 Datasets?

cs.LG ·2026-11-06 ·Laurits Fredsgaard, Michael Riis Andersen, Mikkel N. Schmidt
benchmark similarity 0.62
Abstract · 33 pages. Preprint of a paper accepted for poster presentation at the AIDaR Workshop at NeurIPS 2026

Absorption, distribution, metabolism, excretion, and toxicity (ADMET) models often rely on small, heterogeneous datasets, yet their predictions may determine which compounds proceed to experimental testing. Useful evaluations must therefore assess both predictive performance and the quality of reported probabilities or intervals. We ask which common uncertainty-quantification methods perform best on the 22 Therapeutics Data Commons (TDC) ADMET datasets and what this benchmark can resolve. We compare eleven calibrated pipelines using nested five-fold cross-validation across ten chemical partitions and five model seeds. Ensemble Monte Carlo (MC) dropout has the best average rank for TDC performance, Brier score, and 90% interval score. For TDC performance, however, it is not separated from the other ensemble pipelines; for Brier and interval score, LightGBM is also not ruled out as best. LightGBM wins more individual datasets than any other method for TDC performance and Brier score, but performs poorly on several endpoints. Smaller evaluations can identify a different leader and often fail to recover the broader comparison. These results make LightGBM and an ensemble neural model complementary baselines. Comparative claims should be checked across multiple chemical partitions using statistical analyses matched to the question being asked.

0.25

Feature Selection for Tabular Foundation Models: Exploring Feature Utility in Low-Data Molecular Prediction

cs.LG ·2026-09-25 ·Yiqi Yao, Miquel Duran-Frigola
code/data similarity 0.62
Abstract · 34 pages, 13 figures, 21 tables, 11 appendices. v3: revised and expanded with held-out FS-Mol test evaluations. Code: https://github.com/ers…

Choosing features is difficult with few labeled molecules, even for a tabular foundation model that learns in context. We study this problem with TabPFN for low-data molecular property prediction, separating input width, feature meaning, and predictive usefulness while keeping contexts, query molecules, and predictor settings matched. On ADME/Tox assays from Therapeutics Data Commons, endpoint-matched assay predictions improve a compact RDKit descriptor baseline, and a provenance audit shows that most audited query molecules already occur in the predictors' training sources. Across 77 FS-Mol development tasks and 157 held-out test assays drawn from ChEMBL, broad RDKit descriptor and fingerprint families provide a strong default, rank-averaging TabPFN with support-fitted fingerprint forests improves upon both models, and learned weighting of family predictions adds further gains at a larger prediction budget. A utility-trained selector builds a traceable 16-column input from 238 sourceassay predictors, improving upon the baseline while trailing wider representations and equalwidth structural SVD coordinates. Named outputs identify what each feature predicts and where it comes from. Their usefulness for a new assay is assessed alongside the other input features, and paired removal and replacement tests measure what each selected output contributes. Together, these studies offer a protocol for evaluating feature selection, representation choice, and data provenance with a fixed tabular foundation model for few-shot molecular property prediction.

0.36

Few-Shot Bioactivity Prediction with Meta-Learning under Assay Heterogeneity

cs.LG ·2026-10-05 ·Michal Kmicikiewicz, Tommy Rochussen, Vincent Fortuin, Ewa Szczurek
similarity 0.62
Abstract

Accurate bioactivity prediction is a central challenge in early-stage drug discovery, as individual assays often contain too few measurements to train reliable models independently. Meta-learning offers a principled approach to this few-shot setting, but assay heterogeneity may limit its effectiveness. Here, we test this hypothesis and show that meta-learning performance degrades as meta-training tasks become more heterogeneous. To address this, we introduce MetaHeta, a meta-learning framework that accounts for assay heterogeneity by conditioning predictions on auxiliary data from related assays, with relatedness defined flexibly from available assay information. The architecture of MetaHeta combines linear attention over large auxiliary datasets with exact attention over scarce task-specific context, enabling efficient scaling to the former without compromising exact attention over the latter. We demonstrate the benefits of our approach on assays from ChEMBL and BindingDB, improving few-shot bioactivity prediction and downstream compound prioritization in retrospective Bayesian optimization.

0.17

Large-scale AI-Ready Data for Anti-Cancer Drug Response Modeling

cs.LG q-bio.QM ·2026-08-11 ·Vincent Lavelle, Yitan Zhu, Kaitlyn Marlor, Thomas Brettin, Rick Stevens
benchmarkdataset similarity 0.60
Abstract

Drug response prediction (DRP) models are an active area of research in pharmacogenomics, with growing potential to accelerate the identification of effective anticancer drugs. However, their predictive performance is often constrained by limited dataset scale and insufficient coverages of cancer and chemical spaces. In addition, inconsistent benchmarking practices hinder reliable comparison across models. Standardized frameworks, such as the Innovative Methodologies and New Data for Predictive Oncology Model Evaluation (IMPROVE) project, provide unified data schemas and evaluation protocols for consistent benchmarking, but improving model generalizability requires larger and more diverse training data. In this work, we substantially expand the IMPROVE benchmark through large-scale integration of pharmacogenomic data, primarily from PharmacoDB, together with additional smaller data sources. The expanded resource includes millions of drug response measurements, broader multi-omics coverage, and a major increase in chemical diversity, adding more than 50,000 compounds. To evaluate the impact of the new dataset compared to the original IMPROVE benchmark dataset, we trained DRP models using the two datasets and assess their prediction performance using a common test set and several evaluation strategies, including drug-blind, cancer-blind, and disjoint data splits. While cancer-blind performance remained comparable to the original benchmark, models trained on the expanded dataset showed consistent improvements in drug-blind and disjoint settings, indicating enhanced generalization to previously unseen compounds. These results position the expanded dataset as a community resource that provides a richer foundation for developing DRP models intended to aid in the discovery of novel anticancer drugs.

0.04

PDO Drug Screening Data for Evaluating and Training AI Drug Response Prediction Models

cs.AI q-bio.QM ·2026-11-11 ·Y. Zhu, K. Marlor, V. Lavelle, T. S. Brettin, M. Sacco +4 more
code/data similarity 0.60
Abstract

Anti-cancer drug response prediction (DRP) is critically important for precision oncology and therapeutic development. Currently, most DRP models are developed using drug screening data from immortalized cancer cell lines, which can differ substantially from patient tumors at the genomic and molecular levels, even though patient tumor response is the ultimate prediction target. To help bridge this gap and bring DRP models closer to their intended clinical application, we conducted four drug screening studies using patient-derived organoids (PDOs), which more faithfully recapitulate patient tumors than immortalized cell lines. These studies generated data for improving and evaluating DRP models, including multi-omics profiles of PDO lines, drug feature data, and treatment response measurements. Using these data, we retrained and evaluated multiple publicly available DRP models under three model-building scenarios: training models using cell line data only, training models using combined cell line and PDO data, and pretraining models on cell line data followed by fine-tuning on PDO data. We then evaluated and compared model prediction performance on PDOs across these analysis scenarios. In addition, we also assessed the consistency of drug screening viability data generated by different laboratories using different assay technologies and/or experimental protocols.

0.36